I analyze oil and gas companies, related companies, and W. P. Carey in my service, Oil & Gas Value Research, where I look for undervalued names in the oil and gas space. I break down everything you need to know about these companies -- the balance sheet, competitive position and development prospects. This article is an example of what I do. But for Oil & Gas Value Research members, they get it first and they get analysis on some companies that is not published on the free site. Interested? Sign up here for ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Gold mining stocks are hot right now. Economic uncertainty, inflation fears and the prospects of a tariff war are making a lot of investors look to traditional flight-to-safety stocks, and gold miners are a classic choice. But precious metals don't begin or endI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Maga ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Group 1 - Exelon Corporation (NASDAQ: EXC) was previously identified as a buy due to its superior performance compared to other utilities across various metrics [1] - The analysis emphasizes the company's potential for value return to investors, highlighting its underappreciated status in the market [1] Group 2 - The author has extensive experience in investment analysis, focusing on deep-discount value plays and contrarian investment philosophy [1]

Core Viewpoint - The individual investor adopts a contrarian investment style, focusing on deep value opportunities, particularly in stocks that have recently experienced sell-offs due to non-recurrent events, while also considering insider buying as a positive signal [1] Investment Strategy - The investment portfolio is split approximately 50%-50% between shares and call options, indicating a balanced approach to risk and potential returns [1] - The investor's timeframe for holding positions typically ranges from 3 to 24 months, suggesting a medium-term investment horizon [1] - Fundamental analysis is employed to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Technical analysis is utilized to optimize entry and exit points, with a focus on support and resistance levels on weekly charts [1] Stock Selection Criteria - The investor screens for stocks that have undergone recent sell-offs, particularly when there is insider buying at the new lower price, indicating potential recovery [1] - Professional background checks are conducted on insiders who purchase shares post-sell-off, adding a layer of due diligence to the investment process [1]

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Core Viewpoint - Bristol Myers Squibb (BMY) presents a compelling investment opportunity despite its 23% decline in 2025, driven by market turbulence, offering deep value and substantial income potential [2][4]. Group 1: Valuation Metrics - Bristol Myers Squibb trades at 7.2 times forward earnings, significantly lower than the S&P 500's 18 times, indicating a nearly 60% discount [5]. - The company offers a 5.12% dividend yield, nearly four times the S&P 500's yield of 1.35%, making it the second highest among major drug manufacturers [6]. Group 2: Market Challenges - Analysts predict a nearly 7% decline in Bristol Myers Squibb's 2026 revenue due to pricing pressures, geopolitical issues, and slowing growth in key franchises [7]. - Significant patent expirations for key drugs like Eliquis and Opdivo starting in 2028 could further impact revenue [8]. - Recent clinical trial failures in key pipeline assets have contributed to investor skepticism [9]. Group 3: Growth Potential - The company's acquisition strategy has diversified its pipeline, with recent acquisitions in oncology and neurology enhancing growth prospects [11]. - Bristol Myers Squibb is actively reducing debt, improving financial flexibility for future acquisitions [12]. - Promising pipeline candidates in cardiology and hematology may mitigate expected revenue declines from patent expirations [13]. Group 4: Investment Opportunity - The stock's current valuation and dividend yield present a contrarian investment opportunity, despite the company's challenges [14]. - For investors willing to accept short-term uncertainty, the current entry point offers a favorable risk-reward proposition [15].